Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Flourishing for Peace

15 novembre 2026 mis à jour par: Universidad del Sinú - Elías Bechara Zainúm

Flourishing for Peace Curriculum (Currículo de Florecimiento Para la Paz)

This study is a six-arm individually randomized group-treated (IRGT) trial comparing five16-week standalone flourishing curricula conditions with a control condition consisting of the regular curriculum. Participants will be individually randomized to one of the six conditions. Self-report variables and heart rate variability (HRV) data will be assessed at four time points: T1 (baseline, before the curriculum begins), T2 (8-week midterm), T3 (16-week, at the end of the curriculum), and T4 (beginning of next term), with the main outcome testing changes between T1 and T3. Primary outcomes include the lnRMSSD as a measure of HRV and the overall self-reported flourishing score. Secondary outcomes include 20 domain specific psychological scales and two other HRV measures (SDNN, and mean heart rate). Course-specific knowledge tests will also be administered to gauge participant engagement and course effectiveness. Study results will be reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines for non-pharmacological interventions.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

1050

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • (a) enrollment as a university student at UniSinu; (b) intention to remain in the campus area for at least 12 months and express a commitment to try to remain engaged in the study from beginning to end; and (c) ability to read, speak, and understand Spanish.

Exclusion Criteria:

  • No

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Resilience and Self-Control

This flourishing curriculum is delivered as a stand-alone, 16-week classroom seminar incorporating lectures, experiential activities, and structured discussions. The content of this curriculum was developed by subject-matter experts.

Resilience and Self-Control

Expérimental: Stress, Coping, and Forgiveness

This flourishing curriculum is delivered as a stand-alone, 16-week classroom seminar incorporating lectures, experiential activities, and structured discussions. The content of this curriculum was developed by subject-matter experts.

Stress, Coping, and Forgiveness

Expérimental: Mindfulness and Meaning and Purpose

This flourishing curriculum combines two courses, and is delivered as a stand-alone, 16-week classroom seminar. Mindfulness will be taught in 8 of the 16 weeks and Meaning and Purpose will be taught in another 8 weeks. Contents incorporate lectures, experiential activities, and structured discussions. The content of this curriculum was developed by subject-matter experts.

Mindfulness and Meaning and Purpose

Expérimental: Quality of Relationships for Peace and Positive Emotions

This flourishing curriculum combines two courses, and is delivered as a stand-alone, 16-week classroom seminar. Quality of Relationships for Peace will be taught in 8 of the 16 weeks and Positive Emotions will be taught in another 8 weeks. Contents incorporate lectures, experiential activities, and structured discussions. The content of this curriculum was developed by subject-matter experts.

Quality of Relationships for Peace and Positive Emotions

Expérimental: Emotional Intelligence, Forgiveness, and Spirituality

This flourishing curriculum is delivered as a stand-alone, 16-week classroom seminar incorporating lectures, experiential activities, and structured discussions. The content of this curriculum was developed by subject-matter experts.

Emotional Intelligence, Forgiveness, and Spirituality

Comparateur actif: Regular course

Participants assigned to the control condition will continue with their regular university coursework but complete the same measures as the intervention conditions.

Regular course

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Overall Flourishing: Flourish Measure
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Use the total score across 10 items of the Flourish measure developed by Tyler VanderWeele. Scale score ranges from 0 to 10. Higher score indicates better outcome.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
lnRMSSD
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Heart rate variability (HRV) will be collected using a validated chest-strap sensor ( the Polar H10; Polar Electro, Kempele, Finland) during standardized resting assessments. The natural logarithm of the root mean square of successive differences between normal RR intervals (lnRMSSD), a time-domain measure of short-term heart rate variability and vagal/parasympathetic regulation, will be used as the primary HRV outcome.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Happiness and Life Satisfaction: subscale of Flourish Measure
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

subscale of the Flourish measure of the primary outcome developed by VanderWeele. Scale score ranges from 0 to 10. Higher score indicates better outcome.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Mental and Physical Health: subscale of Flourish Measure
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

subscale of the Flourish measure of the primary outcome developed by VanderWeele. Scale score ranges from 0 to 10. Higher score indicates better outcome.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Meaning and Purpose: subscale of Flourish Measure
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

subscale of the Flourish measure of the primary outcome developed by VanderWeele. Scale score ranges from 0 to 10. Higher score indicates better outcome.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Character and Virtue: subscale of Flourish Measure
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

subscale of the Flourish measure of the primary outcome developed by VanderWeele. Scale score ranges from 0 to 10. Higher score indicates better outcome.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Close Social Relationships: subscale of Flourish Measure
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

subscale of the Flourish measure of the primary outcome developed by VanderWeele. Scale score ranges from 0 to 10. Higher score indicates better outcome.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Depression symptoms: Patient Health Questionnaire-9 (PHQ-9)
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 0 to 3. Higher score indicates more severe depressive symptoms.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Anxiety Symptoms: Generalized Anxiety Disorder-7 (GAD-7)
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 0 to 3. Higher scores more severe anxiety symptoms.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
The Short Stress Overload Scale
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 1 to 5. Higher score indicates higher stress.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Coherence: subscale of the Three Dimensional Meaning in Life Scale (3DM)
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 1 to 7. Higher score indicates higher meaning.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Purpose: subscale of the Three Dimensional Meaning in Life Scale (3DM)
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 1 to 7. Higher score indicates higher meaning.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Significance: subscale of the Three Dimensional Meaning in Life Scale (3DM)
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 1 to 7. Higher score indicates higher meaning.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Trait Forgivingness Scale
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 1 to 5. Higher score indicates higher forgiveness.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Trait Humility: subscale of Relational Humility Scale
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 1 to 5. Higher score indicates higher humility.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 1 to 4. Higher score indicates higher mindfulness.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Brief Self-Control Scale
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 1 to 5. Higher score indicates higher self-control

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Brief Resilience Scale
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 1 to 5. Higher score indicates higher resilience.

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Loneliness: NIH Toolbox Adult Social Relationship Scales
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 1 to 5. Higher score indicates higher level of loneliness

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Transcendent Spirituality: subscale of Trait Sources of Spirituality Scale
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 1 to 5. Higher score indicates higher level of spirituality

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Persevering Hope Scale
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 1 to 5. Higher score indicates higher level of hope

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Coping Self-Efficacy Scale
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Scale score ranges from 0 to 10. Higher score indicates higher level of self-efficacy

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
SDNN
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Standard Deviation of Normal-to-Normal intervals, another HRV measure

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up
Mean Heart Rate
Délai: T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Mean Heart Rate

T1 Baseline, T2 End of 8 weeks, T3 End of 16 weeks, T4 6-month Follow-up

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 janvier 2027

Achèvement primaire (Estimé)

1 août 2027

Achèvement de l'étude (Estimé)

1 décembre 2027

Dates d'inscription aux études

Première soumission

15 novembre 2026

Première soumission répondant aux critères de contrôle qualité

15 novembre 2026

Première publication (Réel)

20 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

15 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • Acta No. 005 de 2025

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .